U.S. Markets open in 8 hrs 40 mins

DermTech, Inc. (DMTK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.40+5.08 (+15.72%)
At close: 4:00PM EDT
Sign in to post a message.
  • r
    roland
    Awesome results!!!
    Bullish
  • B
    BlueWater
    Based on earning results, DMTK will return to 40-45 range.
    In 2-3 years well on its way to a market cap of 6-8 Billion (stock price: $180 to #250)
  • S
    StephenUK
    Not expecting stellar results today BUT I have bought today because I anticipate a flurry of contracts during the coming months following the appointment of a large sales force
    Bullish
  • P
    Prem
    I just realized as I was reading their press release that some (probably a lot) of the short interest is related to the outstanding warrants; the warrant holders must be delta hedging the underlying stock by borrowing and selling short
  • G
    Get em
    I've seen this climb a few times over the last 6 months. Hopefully this time it sticks
    Bullish
  • I
    Iyke
    Still not convinced they are growing fast enough to command this valuation. The revenue growth figures are compared to last year when they practically had no sales due to the pandemic. This stock is still top priced for perfection.
  • J
    Jeremy
    anyone have AH price. Yahoo hasn't updated it.
  • J
    Jeremy
    had my dermatologist appointment today. I asked him about dermtech. He said he didn't know when but eventually it will be the gold standard. He is not presently using it because of insurance billing but is hopefull he can soon.
  • G
    Growthman
    very good results
    Bullish
  • P
    Prem
    Back to high 30s/low 40s for another 3-months
  • M
    MAC81
    Definitely headed back into the 40's after this no problem.
  • b
    bioimmunomabman
    So much for the theory that all of the shorters are warrant holders who are hedging and there's no active short position.
  • P
    Prem
    Not widely reported but the company recently announced a 10-year lease (with extension options) of a lot of office and lab space in San Diego; it very much looks like they are methodically executing on their business plan and are not distracted by the volatility in their stock price

    This is what you want to see
  • P
    Prem
    Earnings are not really a big driver of the valuation of DMTK at this stage; how quickly they are advancing the adoption and acceptance of their products in the dermatology practices is the key; they need to push it past a tipping point, which will be the main catalyst for the stock’s valuation

    I am sure a few established diagnostics companies are also looking at DMTK as well; there are decent synergies for this product within an existing portfolio; that is an alternative path to value, perhaps the likely one at this stage
  • P
    Prem
    This is a ‘no drama’ management; methodical, steady, eyes on the ball, and no overselling
  • L
    Lovepreet
    Anyone worried about earnings?
  • E
    E
    If you ever been subject to skin exams and tests, you understand how big this can be. Question is not if this will be big, but when and how much more cash, and possible dilution will it take
  • f
    faarnorth
    Strategic Investors ceo just made a positive 5 bagger prediction for next 5 years on Fox Business.
    Can anyone tell us what the news was In January that propelled it higher ?
  • I
    Iyke
    Stock is just trading sideways because it’s 152 price to sales. Will take at least another year to grow into this bloated valuation. Not buying at anything more than $26